In vitro biological activity of resveratrol using a novel inhalable resveratrol spray-dried formulation

International Journal of Pharmaceutics

Volumn 491, Issue 1-2, 2015, Pages 190-197

  Trotta, Valentina ^a,b   Lee, Wing Hin ^a   Loo, Ching Yee ^a   Haghi, Mehra ^c   Young, Paul M ^a   Scalia, Santo ^b   Traini, Daniela ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

Calu 3; Inflammation; Inhalation; Oxidation; Resveratrol; Spray dried

Indexed keywords

ASCORBIC ACID; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; RESVERATROL; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; ANTIOXIDANT; NONSTEROID ANTIINFLAMMATORY AGENT; SCAVENGER; STILBENE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MANUFACTURE; DRUG TOLERABILITY; DRY POWDER; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPRAY DRYING; BIOSYNTHESIS; CELL LINE; CELL SURVIVAL; DESICCATION; DRUG EFFECTS; DRY POWDER INHALER; EPITHELIUM CELL; INHALATIONAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; PARTICLE SIZE; PHYSIOLOGICAL STRESS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADMINISTRATION, INHALATION; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; CELL LINE; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DESICCATION; DRY POWDER INHALERS; EPITHELIAL CELLS; FREE RADICAL SCAVENGERS; HUMANS; INTERLEUKIN-8; LIPOPOLYSACCHARIDES; PARTICLE SIZE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; STILBENES; STRESS, PHYSIOLOGICAL; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84934342874     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.06.033     Document Type: Article

References (56)

1. R. Acquaviva, A. Russo, A. Campisi, V. Sorrenti, C. Giacomo, M. Barcellona, M. Avitabile, and A. Vanella Antioxidant activity and protective effect on DNA cleavage of resveratrol J. Food Sci. 67 2002 137 141
2. A. Amri, J. Chaumeil, S. Sfar, and C. Charrueau Administration of resveratrol: what formulation solutions to bioavailability limitations? J. Control. Release 158 2012 182 193
3. T.S. Anekonda Resveratrol - a boon for treating Alzheimer's disease? Brain Res. Rev. 52 2006 316 326
4. K.A. Ansari, P.R. Vavia, F. Trotta, and R. Cavalli Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study AAPS PharmSciTech. 12 2011 279 286
5. I.C. Arts, and P.C. Hollman Polyphenols and disease risk in epidemiologic studies Am. J. Clin. Nutr. 81 2005 317S 325S
6. P.J. Barnes Chronic obstructive pulmonary disease: a growing but neglected global epidemic PLoS Med. 4 2007 e112
7. P.J. Barnes, and I.M. Adcock Glucocorticoid resistance in inflammatory diseases Lancet 373 2009 1905 1917
8. P.J. Barnes, K. Ito, and I.M. Adcock Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase Lancet 363 2004 731 733
9. P.J. Barnes, K. Ito, and I.M. Adcock Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase Lancet 363 2004 731 733
10. P. Basnet, H. Hussain, I. Tho, and N. Skalko-Basnet Liposomal delivery system enhances anti-inflammatory properties of curcumin J. Pharm. Sci. 101 2012 598 609
11. X.L. Bi, J.Y. Yang, Y.X. Dong, J.M. Wang, Y.H. Cui, T. Ikeshima, Y.Q. Zhao, and C.F. Wu Resveratrol inhibits nitric oxide and TNF-α production by lipopolysaccharide-activated microglia Int. Immunopharmacol. 5 2005 185 193
12. P.M. Calverley, J.A. Anderson, B. Celli, G.T. Ferguson, C. Jenkins, P.W. Jones, J.C. Yates, and J. Vestbo Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease N. Engl. J. Med. 356 2007 775 789
13. M. Cazzola, F. Di Perna, P. Noschese, A. Vinciguerra, F. Calderaro, G. Girbino, and M. Matera Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD Eur. Respir. J. 11 1998 1337 1341
14. B. Celli, W. MacNee, A. Agusti, A. Anzueto, B. Berg, A. Buist, P. Calverley, N. Chavannes, T. Dillard, and B. Fahy Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper Eur. Respir. J. 23 2004 932 946
15. A.M. Cerqueira, N. Khaper, S.J. Lees, and M. Ulanova The antioxidant resveratrol down-regulates inflammation in an in-vitro model of Pseudomonas aeruginosa infection of lung epithelial cells 1 Can. J. Physiol. Pharmacol. 91 2013 248 255
16. N.Y. Chew, P. Tang, H.-K. Chan, and J.A. Raper How much particle surface corrugation is sufficient to improve aerosol performance of powders Pharm. Res. 22 2005 148 152
17. J. Choi, Q. Zhang, V. Reipa, N.S. Wang, M.E. Stratmeyer, V.M. Hitchins, and P.L. Goering Comparison of cytotoxic and inflammatory responses of photoluminescent silicon nanoparticles with silicon micron-sized particles in RAW 264.7 macrophages J. Appl. Toxicol. 29 2009 52 60
18. B.P. Commission, and G. Britain British Pharmacopoeia 2011 2010 Stationery Office
19. C.J. Cooper, M.J. Landzberg, T.J. Anderson, F. Charbonneau, M.A. Creager, P. Ganz, and A.P. Selwyn Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans Circulation 93 1996 266 271
20. S. Culpitt, D. Rogers, P. Fenwick, P. Shah, C. De Matos, R. Russell, P. Barnes, and L. Donnelly Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD Thorax 58 2003 942 946
21. R. Dahl, K.F. Chung, R. Buhl, H. Magnussen, V. Nonikov, D. Jack, P. Bleasdale, R. Owen, M. Higgins, and B. Kramer Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD Thorax 65 2010 473 479
22. S. Das, and D.K. Das Resveratrol: a therapeutic promise for cardiovascular diseases Recent Pat. Cardiovasc. Drug Discov. 2 2007 133 138
23. L.E. Donnelly, R. Newton, G.E. Kennedy, P.S. Fenwick, R.H. Leung, K. Ito, R.E. Russell, and P.J. Barnes Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms Am. J. Physiol. Lung Cell. Mol. Physiol. 287 2004 L774 L783
24. L.E. Donnelly, R. Newton, G.E. Kennedy, P.S. Fenwick, R.H. Leung, K. Ito, R.E. Russell, and P.J. Barnes Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms Am. J. Physiol. Lung Cell. Mol. Physiol. 287 2004 L774 L783
25. B.L. Fiebich, K. Lieb, S. Engels, and M. Heinrich Inhibition of LPS-induced p42/44 MAP kinase activation and iNOS/NO synthesis by parthenolide in rat primary microglial cells J. Neuroimmunol. 132 2002 18 24
26. A. Francioso, P. Mastromarino, R. Restignoli, A. Boffi, M. d'Erme, and L. Mosca Improved stability of trans-resveratrol in aqueous solutions by carboxymethylated (1,3/1,6)-beta-d-glucan J. Agric. Food Chem. 62 2014 1520 1525
27. M. Haghi, D. Traini, and P. Young In vitro cell integrated impactor deposition methodology for the study of aerodynamically relevant size fractions from commercial pressurised metered dose inhalers Pharm. Res. 31 2014 1779 1787
28. M. Haghi, P.M. Young, D. Traini, R. Jaiswal, J. Gong, and M. Bebawy Time- and passage-dependent characteristics of a Calu-3 respiratory epithelial cell model Drug Dev. Ind. Pharm. 36 2010 1207 1214
29. T. Harju, R. Kaarteenaho-Wiik, Y. Soini, R. Sormunen, and V.L. Kinnula Diminished immunoreactivity of γ-glutamylcysteine synthetase in the airways of smokers' lung Am. J. Respir. Crit. Care Med. 166 2002 754 759
30. J. Knobloch, H. Hag, D. Jungck, K. Urban, and A. Koch Resveratrol impairs the release of steroid-resistant cytokines from bacterial endotoxin-exposed alveolar macrophages in chronic obstructive pulmonary disease Basic Clin. Pharmacol. Toxicol. 109 2011 138 143
31. J. Knobloch, B. Sibbing, D. Jungck, Y. Lin, K. Urban, E. Stoelben, J. Strauch, and A. Koch Resveratrol impairs the release of steroid-resistant inflammatory cytokines from human airway smooth muscle cells in chronic obstructive pulmonary disease J. Pharmacol. Exp. Ther. 335 2010 788 798
32. J. Knobloch, C. Wahl, M. Feldmann, D. Jungck, J. Strauch, E. Stoelben, and A. Koch Resveratrol attenuates the release of inflammatory cytokines from human bronchial smooth muscle cells exposed to lipoteichoic acid in chronic obstructive pulmonary disease Basic Clin. Pharmacol. Toxicol. 114 2014 202 209
33. A. Kode, S. Rajendrasozhan, S. Caito, S.-R. Yang, I.L. Megson, and I. Rahman Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells Am. J. Physiol. Lung Cell. Mol. Physiol 294 2008 L478 L488
34. I.-T. Lee, and C.-M. Yang Role of NADPH oxidase/ROS in pro-inflammatory mediators-induced airway and pulmonary diseases Biochem. Pharmacol. 84 2012 581 590
35. D.Y. Leung, and S.J. Szefler New insights into steroid resistant asthma Pediatr. Allergy Immunol. 9 1998 3 12
36. P.L. Liu, J.R. Tsai, A.L. Charles, J.J. Hwang, S.H. Chou, Y.H. Ping, F.Y. Lin, Y.L. Chen, C.Y. Hung, and W.C. Chen Resveratrol inhibits human lung adenocarcinoma cell metastasis by suppressing heme oxygenase 1-mediated nuclear factor-κB pathway and subsequently downregulating expression of matrix metalloproteinases Mol. Nutr. Food Res. 54 2010 S196 S204
37. L.H. Long, A. Hoi, and B. Halliwell Instability of, and generation of hydrogen peroxide by, phenolic compounds in cell culture media Arch. Biochem. Biophys. 501 2010 162 169
38. M. Man-Ying Chan, J.A. Mattiacci, H.S. Hwang, A. Shah, and D. Fong Synergy between ethanol and grape polyphenols, quercetin, and resveratrol, in the inhibition of the inducible nitric oxide synthase pathway Biochem. Pharmacol. 60 2000 1539 1548
39. S.K. Manna, A. Mukhopadhyay, and B.B. Aggarwal Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-κB, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation J. Immunol. 164 2000 6509 6519
40. R. Newton, L.M.E. Kuitert, M. Bergmann, I.M. Adcock, and P.J. Barnes Evidence for involvement of NF-κB in the transcriptional control of COX-2 gene expression by IL-1β Biochem. Biophys. Res. Commun. 237 1997 28 32
41. R.A. Pauwels, A.S. Buist, P.M. Calverley, C.R. Jenkins, S.S. Hurd, and G.S. Committee Global strategy for the diagnosis management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary Am. J. Respir. Crit. Care Med. 163 2001 1256 1276
42. R.A. Pauwels, C.-G. Löfdahl, L.A. Laitinen, J.P. Schouten, D.S. Postma, N.B. Pride, and S.V. Ohlsson Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking N. Engl. J. Med. 340 1999 1948 1953
43. I. Rahman Review: antioxidant therapeutic advances in COPD Ther. Adv. Respir. Dis. 2 2008 351 374
44. I. Rahman, and I. Adcock Oxidative stress and redox regulation of lung inflammation in COPD Eur. Respir. J. 28 2006 219 242
45. I. Rahman, and W. MacNee Oxidative stress and regulation of glutathione in lung inflammation Eur. Respir. J. 16 2000 534 554
46. C. Santangelo, R. Varì, B. Scazzocchio, R. Di Benedetto, C. Filesi, and R. Masella Polyphenols, intracellular signalling and inflammation Ann. Ist. Super Sanita 43 2007 394
47. S. Scalia, M. Haghi, V. Losi, V. Trotta, P.M. Young, and D. Traini Quercetin solid lipid microparticles: a flavonoid for inhalation lung delivery Eur. J. Pharm. Sci. 49 2013 278 285
48. S. Selvaraj, A. Mohan, S. Narayanan, S. Sethuraman, and U.M. Krishnan Dose-dependent interaction of trans-resveratrol with biomembranes: effects on antioxidant property J. Med. Chem. 56 2013 970 981
49. E.K. Silverman, H.A. Chapman, J.M. Drazen, S.T. Weiss, B. Rosner, E.J. Campbell, W.J. O'Donnell, J.J. Reilly, L. Ginns, and S. Mentzer Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease: risk to relatives for airflow obstruction and chronic bronchitis Am. J. Respir. Crit. Care Med. 157 1998 1770 1778
50. D.G. Soares, A.C. Andreazza, and M. Salvador Sequestering ability of butylated hydroxytoluene, propyl gallate, resveratrol, and vitamins C and E against ABTS, DPPH, and hydroxyl free radicals in chemical and biological systems J. Agric. Food Chem. 51 2003 1077 1080
51. S. Stojanović, H. Sprinz, and O. Brede Efficiency and mechanism of the antioxidant action of trans-resveratrol and its analogues in the radical liposome oxidation Arch. Biochem. Biophys. 391 2001 79 89
52. J. Todoroff, and R. Vanbever Fate of nanomedicines in the lungs Curr. Opin. Colloid Interface Sci. 16 2011 246 254
53. C. Vogelmeier, B. Hederer, T. Glaab, H. Schmidt, M.P. Rutten-van Mölken, K.M. Beeh, K.F. Rabe, and L.M. Fabbri Tiotropium versus salmeterol for the prevention of exacerbations of COPD N. Engl. J. Med. 364 2011 1093 1103
54. L.G. Wood, P.A.B. Wark, and M.L. Garg Antioxidant and anti-inflammatory effects of resveratrol in airway disease Antioxid. Redox Signal. 13 2010 1535 1548
55. J.M. Wu, Z.-R. Wang, T.-C. Hsieh, J.L. Bruder, J.-G. Zou, and Y.-Z. Huang Mechanism of cardioprotection by resveratrol, a phenolic antioxidant present in red wine (Review) Int. J. Mol. Med. 8 2001 3 17
56. N.-C. Yang, C.-H. Lee, and T.-Y. Song Evaluation of resveratrol oxidation in vitro and the crucial role of bicarbonate ions Biosci. Biotechnol. Biochem. 74 2010 63 68